GLPG 2938Alternative Names: GLPG2938
Latest Information Update: 17 Jun 2016
At a glance
- Originator Galapagos NV
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Idiopathic pulmonary fibrosis
Most Recent Events
- 15 Jun 2016 Preclinical trials in Idiopathic pulmonary fibrosis in Belgium (unspecified route)